ERBB2 and breast cancer: Cell-based studies using HER2-overexpressing SKBR3 breast cancer cells demonstrated specific binding of trastuzumab-Mal-SAC4A/Dox complex to tumor cells, as confirmed by confocal laser scanning microscopy.